Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€159.06
Target price
12.09.17
€171.38
Performance (%)
7.96%
End price
12.09.17
€171.72
Summary
This prediction ended on 12.09.17 with a price of €171.72. The BUY prediction by melinda finished with a performance of 7.96%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | -0.621% | -0.621% | 11.190% | 12.327% |
| iShares Core DAX® | 0.323% | 2.208% | 21.610% | 72.184% |
| iShares Nasdaq 100 | 0.145% | -0.987% | 5.603% | 112.977% |
| iShares Nikkei 225® | 0.091% | -1.421% | 12.897% | 46.571% |
| iShares S&P 500 | 0.371% | -0.469% | 3.470% | 68.947% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
zu folgen
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom